Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer.

Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer.

Item
http://www.wikidata.org/entity/Q33939772
Positron Emission Tomography in Breast CancerThe application of positron emission tomography (PET/CT) in diagnosis of breast cancer. Part II. Diagnosis after treatment initiation, future perspectivesEstrogen Receptor-Targeted Contrast Agents for Molecular Magnetic Resonance Imaging of Breast Cancer Hormonal Status.A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC).Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer.PET Tracers for Clinical Imaging of Breast Cancer.Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET.Synthesis of Clinical-Grade [(18)F]-Fluoroestradiol as a Surrogate PET Biomarker for the Evaluation of Estrogen Receptor-Targeting Therapeutic DrugFailed PET Application Attempts in the Past, Can We Avoid Them in the Future?Assessment of the novel estrogen receptor PET tracer 4-fluoro-11β-methoxy-16α-[(18)F]fluoroestradiol (4FMFES) by PET imaging in a breast cancer murine model.Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials.18F-16α-17β-Fluoroestradiol Binding Specificity in Estrogen Receptor-Positive Breast Cancer.High specific activity is not optimal: 18 F-fluoroestradio positron emission tomography-computed tomography results in a breast cancer xenograft.Utility of 18F-fluoroestradiol (18F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy.
P2860

Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer.

Item
http://www.wikidata.org/entity/Q33939772
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Factors influencing the uptake ...... ceptor positive breast cancer.
@ast
Factors influencing the uptake ...... ceptor positive breast cancer.
@en
type
label
Factors influencing the uptake ...... ceptor positive breast cancer.
@ast
Factors influencing the uptake ...... ceptor positive breast cancer.
@en
prefLabel
Factors influencing the uptake ...... ceptor positive breast cancer.
@ast
Factors influencing the uptake ...... ceptor positive breast cancer.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P921
P932
P356
P1433
P1476
Factors influencing the uptake ...... ceptor positive breast cancer.
@en
P2093
P2860
P304
P31
P356
10.1016/J.NUCMEDBIO.2011.03.002
P433
P478
P577
P698
P921
P932